A 35-yr-old patient is having carcinoma lung with a past history of lung disease. Which of the following drugs should not be given?
## **Core Concept**
The question revolves around the management of a patient with lung carcinoma and a history of lung disease, focusing on the potential impact of certain drugs on lung function. The key principle here involves understanding the pulmonary toxicity associated with various chemotherapeutic agents.
## **Why the Correct Answer is Right**
Bleomycin is a chemotherapeutic agent known for its pulmonary toxicity, which can lead to pneumonitis and pulmonary fibrosis. This side effect is dose-dependent and can be severe enough to necessitate discontinuation of the drug. Given the patient's history of lung disease and current diagnosis of lung carcinoma, administering bleomycin could exacerbate lung function, making it a risky choice.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not specified, but if we consider common chemotherapeutic agents, many do not have the same level of pulmonary toxicity as bleomycin.
- **Option B:** Similarly, without specifics, if these drugs do not have significant pulmonary toxicity, they might be safer in this context.
- **Option D:** Again, lacking details, if these options do not carry the same risk of pulmonary toxicity as bleomycin, they could be considered safer.
## **Clinical Pearl / High-Yield Fact**
A critical point to remember is that **bleomycin** can cause pulmonary fibrosis, a potentially fatal side effect. This makes it a drug to avoid in patients with pre-existing lung conditions. A useful mnemonic to recall drugs associated with pulmonary fibrosis is to think of "BLEO" (Bleomycin) and its pulmonary toxicity.
## **Correct Answer: B. Bleomycin.**